ACCELERON PHARMA INC Insider Trading for February 2021
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in ACCELERON PHARMA INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in ACCELERON PHARMA INC for February 2021.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Option Exercise | A | 115.53 | 18,806 | 2,172,657 | 18,806 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Veness Adam M | SVP, General Counse ... | Grant | A | 0.00 | 4,868 | 0 | 21,031 | 16.2 K to 21 K (+30.12 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Option Exercise | A | 115.53 | 18,806 | 2,172,657 | 18,806 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCLAUGHLIN KEVIN F | SVP, CFO and Treasu ... | Grant | A | 0.00 | 4,868 | 0 | 10,681 | 5.8 K to 10.7 K (+83.74 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Option Exercise | A | 115.53 | 20,896 | 2,414,115 | 20,896 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | KANGO SUJAY | EVP, Chief Commerci ... | Grant | A | 0.00 | 5,409 | 0 | 19,396 | 14 K to 19.4 K (+38.67 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Option Exercise | A | 115.53 | 20,896 | 2,414,115 | 20,896 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Backstrom Jay T. | EVP, Research and D ... | Grant | A | 0.00 | 5,409 | 0 | 20,781 | 15.4 K to 20.8 K (+35.19 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Option Exercise | A | 115.53 | 64,361 | 7,435,626 | 64,361 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Dable Habib J | CEO and President | Grant | A | 0.00 | 16,662 | 0 | 98,450 | 81.8 K to 98.5 K (+20.37 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Zakrzewski Joseph S | Director | Grant | A | 0.00 | 1,622 | 0 | 34,499 | 32.9 K to 34.5 K (+4.93 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Smith Karen L. | Director | Grant | A | 0.00 | 1,622 | 0 | 4,561 | 2.9 K to 4.6 K (+55.19 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | MCCOURT Thomas A | Director | Grant | A | 0.00 | 1,622 | 0 | 6,044 | 4.4 K to 6 K (+36.68 %) |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Option Exercise | A | 115.53 | 3,222 | 372,238 | 3,222 | |
| Feb 02 2021 | XLRN | ACCELERON PHARMA I ... | Malik Kemal | Director | Grant | A | 0.00 | 1,622 | 0 | 1,622 | 0 to 1.6 K |